These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20868293)

  • 41. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
    Zumla AI; Gillespie SH; Hoelscher M; Philips PP; Cole ST; Abubakar I; McHugh TD; Schito M; Maeurer M; Nunn AJ
    Lancet Infect Dis; 2014 Apr; 14(4):327-40. PubMed ID: 24670627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Incidence of resistance and risk factors for resistance in Mycobacterium tuberculosis. A retrospective study of 1,055 patients of a specialty hospital 1984 to 1993].
    Borchardt J; Kirsten D; Jörres R; Kroeger C; Magnussen H
    Pneumologie; 1996 Jan; 50(1):28-35. PubMed ID: 8774932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
    Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.
    Zumla A; Chakaya J; Centis R; D'Ambrosio L; Mwaba P; Bates M; Kapata N; Nyirenda T; Chanda D; Mfinanga S; Hoelscher M; Maeurer M; Migliori GB
    Lancet Respir Med; 2015 Mar; 3(3):220-34. PubMed ID: 25773212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment.
    Engohang-Ndong J
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1789-800. PubMed ID: 22991970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent developments in the treatment of tuberculosis.
    Davies PD; Yew WW
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1297-312. PubMed ID: 12882618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Levofloxacin (Tavanic) in complex therapy of tuberculosis].
    Sokolova GB; Kunichan AD; Lazareva IaV
    Antibiot Khimioter; 2009; 54(1-2):31-7. PubMed ID: 19499715
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current status and research strategies in tuberculosis drug development.
    Dover LG; Coxon GD
    J Med Chem; 2011 Sep; 54(18):6157-65. PubMed ID: 21823589
    [No Abstract]   [Full Text] [Related]  

  • 50. Bedaquiline for the treatment of drug-resistant tuberculosis.
    Bélard S; Heuvelings CC; Janssen S; Grobusch MP
    Expert Rev Anti Infect Ther; 2015 May; 13(5):535-53. PubMed ID: 25797824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tuberculosis treatment and drug regimens.
    Sotgiu G; Centis R; D'ambrosio L; Migliori GB
    Cold Spring Harb Perspect Med; 2015 Jan; 5(5):a017822. PubMed ID: 25573773
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents.
    Cooper CB
    J Med Chem; 2013 Oct; 56(20):7755-60. PubMed ID: 23927683
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
    Wasserman S; Meintjes G; Maartens G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):901-15. PubMed ID: 27532292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preventing multidrug-resistant tuberculosis and errors in tuberculosis treatment around the globe.
    Manangan LP; Jarvis WR
    Chest; 2000 Mar; 117(3):620-3. PubMed ID: 10712980
    [No Abstract]   [Full Text] [Related]  

  • 55. Antituberculosis therapy for 2012 and beyond.
    Lauzardo M; Peloquin CA
    Expert Opin Pharmacother; 2012 Mar; 13(4):511-26. PubMed ID: 22332895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Preclinical and clinical trials of the new tuberculosis drug perchlozon].
    Yablonskiy PK; Vinogradova TI; Levashev YN; Pavlova MV; Zilber EK; Starshinova AA; Sapozhnikova NV; Chernokhaeva IV; Archakova LI; Zabolotnykh NV; Vitovskaya ML
    Ter Arkh; 2016; 88(3):111-115. PubMed ID: 27195324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unorthodox approach to the development of a new antituberculosis therapy.
    Barry CE
    N Engl J Med; 2009 Jun; 360(23):2466-7. PubMed ID: 19494223
    [No Abstract]   [Full Text] [Related]  

  • 58. Empiric tuberculosis treatment in retreatment patients in high HIV/tuberculosis-burden settings.
    Balasegaram M; Brigden G
    Lancet Infect Dis; 2014 Sep; 14(9):795-6. PubMed ID: 25164192
    [No Abstract]   [Full Text] [Related]  

  • 59. [Evaluation of the efficacy of a plant adaptogen (spirulina) in the pathognic therapy of primary tuberculosis in children].
    Kostromina VP; Derkach OV; Symonenkova NV; Riechkina OO; Otroshchenko AO
    Lik Sprava; 2003; (5-6):102-5. PubMed ID: 14618819
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antituberculosis drug resistance: practical solutions to practical problems.
    Tayler E
    J Med Microbiol; 1997 Jul; 46(7):531-3. PubMed ID: 9236735
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.